
FDA approves generic testosterone replacement gel Watson Pharmaceuticals has received FDA approval on its abbreviated new drug application for a generic version of testosterone gel 1% CIII. The drug is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. ![]() designed to meet the evolving needs of physicians, nurses and other allied healthcare professionals. | ![]() Stay Connected to Urology Times • Current Issue • Issue Archive • Subscribe to Print Edition • Subscribe to Digital Edition • Urology Times Radio • Events Calendar Coding Counselor Simple and accurate ICD-9 code search. Start Here Formulary Counselor Find health plan drug coverage in your area. Start Here Patient Education Print customized patient education handouts. Start Here Surgical Video Center On-demand surgery demos and presentations. Start Here ![]() ![]() Featured Jobs |